Thymalin monograph

Thymalin

Overview

Thymalin is a thymus-derived polypeptide complex marketed in some countries as an immunomodulatory/geroprotective peptide. The human evidence base is small, old, and heavily concentrated in Russian literature; there is no FDA-approved U.S. product and no well-established pharmacokinetic profile in humans. Claims of broad anti-aging, immune-boosting, or performance effects are not well validated and should be treated cautiously.

Pharmacokinetics & Mechanism

• Class: Thymic peptide complex / immunomodulatory peptide bioregulator
• Mechanism of action: Not fully established in humans. The best-described human data suggest Thymalin can increase functional activity of T lymphocytes and may promote differentiation of human hematopoietic stem/progenitor cells toward more mature CD28+ T-lymphocyte phenotypes, with reported reductions in CD44 and CD117 expression in one study. Older gerontology literature describes normalization of immune, endocrine, cardiovascular, nervous-system, and metabolic indices, but that is not a precise molecular mechanism.
• Target(s): Not well established. Reported biological signals include T-lymphocytes, hematopoietic stem cells, CD28, CD44, and CD117; broader claims refer to thymus/immune-system regulation rather than a single receptor target. No validated human receptor binding target is established.
• Route(s) of administration: Not well established from high-quality human sources. The published abstracts located do not specify a standard route; Thymalin is generally discussed as an injectable peptide preparation in regional use and in experimental studies involving local injection, but a universally established clinical route is not confirmed in the sources reviewed.
• Onset: Not well established. No human pharmacodynamic onset has been established from authoritative sources; effects in the available literature are described over treatment courses rather than after a single dose.
• Half-life: Not well established. No reliable human half-life could be confirmed from PubMed/authoritative monographs in the sources reviewed. If community sources claim a half-life, treat it as anecdotal unless tied to a formal label or PK study.
• Metabolism / clearance: Not well established. No validated human metabolism or clearance pathway was identified in the authoritative sources reviewed. As a peptide, it would be expected to undergo proteolytic degradation, but that is a general peptide principle rather than a documented Thymalin-specific human clearance pathway.